Therapy Areas: Cardiovascular
Avacta Therapeutics reports positive Phase 1 data for lead candidate
28 April 2025 -

Life sciences company Avacta Therapeutics (AIM: AVCT) announced on Monday that it presented compelling Phase 1 clinical data for its...

Innovent's limertinib receives Chinese regulatory approval for first-line treatment of lung cancer
28 April 2025 - Innovent Biologics Inc (HKEX:01801), a China-based biopharmaceutical company that develops, manufactures and commercialises medicines for the treatment of oncologic, autoimmune, cardio...
Primo Biotechnology's Taoyuan facility granted PIC/S GMP Certification
25 April 2025 - Primo Biotechnology Co, Ltd, a Taiwan-based radiopharmaceutical company, announced on Thursday that its Taoyuan pharmaceutical facility has successfully passed inspection by Taiwan Foo...
Renibus Therapeutics completes RBT-1 Phase 3 clinical trial enrolment
25 April 2025 - Renibus Therapeutics, a US-based clinical late-stage biopharmaceutical company focusing on the prevention and treatment of cardiac, renal, and metabolic diseases, on Thursday announced...
Rona Therapeutics granted Chinese approval of IND application for hypertension drug candidate RN1871
22 April 2025 - Chinese biotechnology company Rona Therapeutics announced on Monday that its Investigational New Drug (IND) application for RN1871, a small interfering RNA (siRNA) drug targeting angio...
Clario partners with AWS on advancing clinical data analysis with generative AI
17 April 2025 - Clario, a US-based provider of endpoint data solutions to the clinical trial industry, announced on Wednesday a multi-year agreement with Amazon Web Services (AWS) to advance its gener...